Clinical trial · Interventional
Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to (1) describe patient and clinician engagement in web-based symptom self-monitoring, (2) identify differences in symptom management between intervention and usual care groups, and (3) identify potential outcomes of real-time symptom tracking and management. With the assistance of the study coordinator, participants randomized to the intervention will create an account with Noona. Patients will be instructed to log symptoms as often as relevant using their own personal devices. Patients will also be prompted once per week for 24 weeks to log any recent symptoms. These participants will be sent a Symptom Questionnaire (SQ) via the Noona tool that summarizes their symptoms and distress one week prior to each oncology clinic visit. Symptoms designated as clinically severe either during regular symptom logging or via the SQ will trigger a prompt to contact the clinical team for immediate follow-up.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Quality of Life | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Use of Noona web- based symptom tracking tool | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Noona web-based symptom tracking tool
- description
- In addition to usual care for their disease, patients interact with Noona system and system questioners to record their symptoms over a period of 6 months.
- interventionNames
- Other: Use of Noona web- based symptom tracking tool
- type
- NO_INTERVENTION
- label
- Usual Care
- description
- Participants will receive the standard of care for their disease
Primary outcomes (3)
- measure
- Proportion of patients with at least one symptom questionnaire (SQ) completed after enrollment using the PROMIS platform
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Individuals (men and women) aged 18 years or older 2. Biopsy proven (recurrent or metastatic) advanced lung or gastrointestinal cancer 3. No limit on prior lines of therapy in the metastatic setting 4. ECOG performance status of 0-2 5. Estimated life expectancy of at least 6 months 6. Access to smartphone, tablet or computer with capability to utilize symptom tracking application 7. Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures 8. Willing and able to comply with all study procedures Exclusion Criteria: 1. Concurrent disease or condition that interferes with participation or safety 2. Non-english speaking, as the application is developed in the english language 3. Non-castrate resistant prostate cancer 4. Enrolled in other non-therapeutic or therapeutic clinical trials
References
Publications (0)
Data not yet available